Q3 2024 |
102 |
$504M |
+$32.4M |
-$51.4M |
-$19M |
CDNA, ENSG, AL, ISRG, WGS
|
13F-HR |
11/12/2024, 06:02 AM |
Q2 2024 |
97 |
$444M |
+$37.5M |
-$19M |
+$18.4M |
AL, CDNA, ENSG, ISRG, PCRX
|
13F-HR |
8/14/2024, 12:59 PM |
Q1 2024 |
98 |
$423M |
+$27.9M |
-$30.8M |
-$2.89M |
AL, ENSG, CDNA, ISRG, PCRX
|
13F-HR |
5/13/2024, 05:16 PM |
Q4 2023 |
102 |
$417M |
+$13.6M |
-$28.8M |
-$15.2M |
AL, ENSG, CDNA, ISRG, PCRX
|
13F-HR |
2/14/2024, 05:15 PM |
Q3 2023 |
97 |
$399M |
+$7.86M |
-$35.1M |
-$27.3M |
AL, ENSG, ISRG, NVGS, PCRX
|
13F-HR |
11/14/2023, 04:06 PM |
Q2 2023 |
97 |
$481M |
+$10.6M |
-$22.5M |
-$11.9M |
AL, ENSG, ISRG, PCRX, PROF
|
13F-HR |
8/8/2023, 05:23 PM |
Q1 2023 |
112 |
$476M |
+$45.8M |
-$25.8M |
+$20M |
AL, ENSG, NVGS, PCRX, CDNA
|
13F-HR |
4/10/2023, 04:08 PM |
Q4 2022 |
106 |
$435M |
+$11.5M |
-$30.1M |
-$18.6M |
AL, ENSG, PCRX, NVGS, PROF
|
13F-HR |
2/7/2023, 04:42 PM |
Q3 2022 |
101 |
$455M |
+$30.5M |
-$28.3M |
+$2.24M |
PCRX, AL, ENSG, CDNA, NVGS
|
13F-HR |
11/14/2022, 04:40 PM |
Q2 2022 |
101 |
$477M |
+$34.9M |
-$22.8M |
+$12.1M |
PCRX, AL, ENSG, NVGS, CDNA
|
13F-HR |
8/1/2022, 04:31 PM |
Q1 2022 |
103 |
$613M |
+$60.1M |
-$45.7M |
+$14.4M |
PCRX, AL, CDNA, ENSG, NVGS
|
13F-HR |
5/9/2022, 05:09 PM |
Q4 2021 |
104 |
$667M |
+$50M |
-$34.4M |
+$15.7M |
AL, AOSL, CDNA, PCRX, ENSG
|
13F-HR |
2/8/2022, 04:06 PM |
Q3 2021 |
112 |
$673M |
+$83M |
-$56.7M |
+$26.3M |
CDNA, AL, PCRX, ENSG, AOSL
|
13F-HR |
11/12/2021, 04:43 PM |
Q2 2021 |
111 |
$704M |
+$65.3M |
-$55.9M |
+$9.34M |
CDNA, AL, ENSG, AMRC, PCRX
|
13F-HR |
7/28/2021, 02:05 PM |
Q1 2021 |
108 |
$657M |
+$59.6M |
-$60M |
-$446K |
CDNA, AL, ENSG, PCRX, GFN
|
13F-HR |
5/14/2021, 05:22 PM |
Q4 2020 |
99 |
$628M |
+$30.2M |
-$14.3M |
+$15.9M |
CDNA, AL, AMRC, ENSG, LLFLQ
|
13F-HR |
2/12/2021, 04:17 PM |
Q3 2020 |
97 |
$467M |
+$24.2M |
-$8.51M |
+$15.7M |
CDNA, AL, PCRX, ENSG, AMRC
|
13F-HR |
11/12/2020, 04:10 PM |
Q2 2020 |
90 |
$413M |
+$16.2M |
-$26.1M |
-$9.82M |
CDNA, AL, PCRX, AMRC, ENSG
|
13F-HR |
8/13/2020, 04:51 PM |
Q1 2020 |
96 |
$294M |
+$27M |
-$70.5M |
-$43.5M |
CDNA, AL, ENSG, AMRC, PCRX
|
13F-HR |
5/11/2020, 04:05 PM |
Q4 2019 |
93 |
$457M |
+$30.2M |
-$35.5M |
-$5.25M |
AL, GFN, CDNA, EVBG, FIVN
|
13F-HR |
2/14/2020, 04:08 PM |
Q3 2019 |
95 |
$423M |
+$12.5M |
-$17.5M |
-$5.03M |
AL, CDNA, GFN, ENSG, FIVN
|
13F-HR |
11/8/2019, 04:10 PM |
Q2 2019 |
97 |
$464M |
+$37.9M |
-$35M |
+$2.91M |
CDNA, AL, ENSG, EVBG, GFN
|
13F-HR |
8/12/2019, 04:05 PM |
Q1 2019 |
97 |
$459M |
+$54.1M |
-$35.1M |
+$19M |
CDNA, AL, ENSG, EVBG, GFN
|
13F-HR |
5/13/2019, 04:10 PM |
Q4 2018 |
93 |
$376M |
+$42.1M |
-$25.4M |
+$16.7M |
CDNA, AL, GFN, ENSG, EVBG
|
13F-HR |
1/18/2019, 04:12 PM |
Q3 2018 |
101 |
$435M |
+$83.6M |
-$20.7M |
+$62.9M |
CDNA, GFN, AL, ENSG, EVBG
|
13F-HR |
11/13/2018, 05:21 PM |
Q2 2018 |
97 |
$337M |
+$46.3M |
-$33.7M |
+$12.7M |
GFN, CDNA, AL, LLFLQ, RHT
|
13F-HR |
8/9/2018, 04:31 PM |
Q1 2018 |
95 |
$281M |
+$9.68M |
-$29.9M |
-$20.2M |
AL, RHT, GFN, CDNA, AMRC
|
13F-HR |
5/9/2018, 05:12 PM |
Q4 2017 |
91 |
$282M |
+$18.5M |
-$17.1M |
+$1.44M |
AL, GFN, CDNA, RHT, FIVN
|
13F-HR |
2/13/2018, 02:51 PM |
Q3 2017 |
95 |
$269M |
+$28.8M |
-$25M |
+$3.8M |
AL, RHT, LLFLQ, FIVN, SU
|
Restatement |
11/14/2017, 05:25 PM |
Q2 2017 |
89 |
$221M |
+$38.6M |
-$47.4M |
-$8.83M |
AL, LLFLQ, FIVN, AMBR, GFN
|
13F-HR |
7/20/2017, 02:55 PM |
Q1 2017 |
95 |
$230M |
+$4.03M |
-$12.5M |
-$8.47M |
AL, LLFLQ, RHT, ATHN, GFNSL
|
13F-HR |
5/11/2017, 04:36 PM |
Q4 2016 |
95 |
$232M |
+$17M |
-$18.7M |
-$1.77M |
AL, RTEC, GFNSL, ATHN, AMBR
|
13F-HR |
2/14/2017, 04:26 PM |
Q3 2016 |
96 |
$235M |
+$57.8M |
-$45.6M |
+$12.3M |
AL, ATHN, AMBR, RTEC, LLFLQ
|
13F-HR |
11/14/2016, 04:31 PM |
Q2 2016 |
91 |
$212M |
+$35.6M |
-$27.3M |
+$8.31M |
ATHN, EQIX, AL, AMBR, RTEC
|
Restatement |
8/24/2016, 10:26 AM |
Q1 2016 |
87 |
$209M |
+$21.8M |
-$20.7M |
+$1.11M |
AL, ATHN, EQIX, RHT, RTEC
|
13F-HR |
5/3/2016, 03:44 PM |
Q4 2015 |
84 |
$218M |
+$4.92M |
-$14.5M |
-$9.53M |
ATHN, RHT, AL, EQIX, RTEC
|
13F-HR |
2/16/2016, 11:51 AM |
Q3 2015 |
86 |
$204M |
+$12.9M |
-$47.7M |
-$34.7M |
RHT, EQIX, AL, ATHN, RTEC
|
13F-HR |
10/16/2015, 11:19 AM |
Q2 2015 |
87 |
$252M |
+$9.27M |
-$37.7M |
-$28.4M |
AL, RHT, EQIX, PSIX, ATHN
|
13F-HR |
7/24/2015, 10:49 AM |
Q1 2015 |
92 |
$301M |
+$22.8M |
-$29.1M |
-$6.27M |
AL, GFN, RHT, PSIX, EQIX
|
13F-HR |
5/12/2015, 05:26 PM |
Q4 2014 |
93 |
$311M |
+$38.9M |
-$42.5M |
-$3.6M |
GFN, EQIX, RHT, CTCT, AL
|
13F-HR |
2/13/2015, 02:07 PM |
Q3 2014 |
97 |
$299M |
+$33.8M |
-$23M |
+$10.8M |
GFN, EQIX, AL, ATHN, RHT
|
13F-HR |
10/15/2014, 04:26 PM |
Q2 2014 |
102 |
$306M |
+$22.8M |
-$44.2M |
-$21.4M |
GFN, AL, EQIX, CTCT, ATHN
|
13F-HR |
7/31/2014, 01:25 PM |
Q1 2014 |
103 |
$337M |
+$46.6M |
-$58.6M |
-$12M |
GFN, AL, ATHN, NVDQ, EQIX
|
13F-HR |
5/6/2014, 04:26 PM |
Q4 2013 |
97 |
$332M |
$0 |
$0 |
|
NVDQ, GFN, ATHN, AL, CTCT
|
Restatement |
2/6/2014, 01:38 PM |